Skip to main content

Advertisement

SpringerLink
Log in

Development of a Time-Resolved Fluorescence Immunoassay for the Diagnosis of Hepatocellular Carcinoma Based on the Detection of Glypican-3

  • ORIGINAL ARTICLE
  • Published:
Journal of Fluorescence Aims and scope Submit manuscript

Abstract

Glypican-3(GPC3), an oncofetal protein, is a potential novel marker for hepatocellular carcinoma (HCC). In this study, we attempted to establish a new method to detect serum GPC3 using the antibodies identified in our previous research, and then evaluated its clinical application for the diagnosis of HCC. Herein, a sandwich time-resolved fluorescence immunoassay (TRFIA) for detecting serum GPC3 was developed. The detection limit, analytical recovery, specificity and precision of the proposed TRFIA assay were satisfactory. A total of 415 patients were collected and divided into seven groups: hepatocellular carcinoma (101), colorectal cancer (67), gastric cancer (44), esophageal cancer (15), cirrhosis (55), hepatitis (61), normal liver (72). Using this proposed method, the concentration of serum GPC3 in these clinical samples was detected. The results demonstrated that the levels of GPC3 in serum from HCC patients were significantly higher than that in others. Compared with the results of chemiluminescence immunoassay (CLIA), a high consistency (Kappa =0.84) was observed. Thus, an effective, sensitive and reliable TRFIA-GPC3 kit for diagnosing HCC was successfully developed. It offers a suitable alternative to existed methods of determining GPC3 and is expected to be used in clinic in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64(1):9–29

    Article  PubMed  Google Scholar 

  2. Ng KK, Lo CM, Liu CL, Poon RT, Chan SC, Fan ST (2008) Survival analysis of patients with transplantable recurrent hepatocellular carcinoma: implications for salvage liver transplant. Arch Surg 143(1):68–74 discussion 74

    Article  PubMed  Google Scholar 

  3. Kim DY, Paik YH, Ahn SH, Youn YJ, Choi JW, Kim JK, Lee KS, Chon CY, Han KH (2007) PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection. Oncology 72(Suppl 1):52–57

    Article  CAS  PubMed  Google Scholar 

  4. Jia HL, Ye QH, Qin LX, Budhu A, Forgues M, Chen Y, Liu YK, Sun HC, Wang L, Lu HZ, Shen F, Tang ZY, Wang XW (2007) Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma. Clin Cancer Res 13(4):1133–1139

    Article  CAS  PubMed  Google Scholar 

  5. Jing X, Piao YF, Liu Y, Gao PJ (2010) Beta 2-GPI: a novel factor in the development of hepatocellular carcinoma. J Cancer Res Clin Oncol 136(11):1671–1680

    Article  CAS  PubMed  Google Scholar 

  6. Sterling RK, Wright EC, Morgan TR, Seeff LB, Hoefs JC, Di Bisceglie AM, Dienstag JL, Lok AS (2012) Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Am J Gastroenterol 107(1):64–74

    Article  CAS  PubMed  Google Scholar 

  7. Yao S, Zhang J, Chen H, Sheng Y, Zhang X, Liu Z, Zhang C (2013) Diagnostic value of immunohistochemical staining of GP73, GPC3, DCP, CD34, CD31, and reticulin staining in hepatocellular carcinoma. J Histochem Cytochem 61(9):639–648

    Article  PubMed  PubMed Central  Google Scholar 

  8. Xiao WK, Qi CY, Chen D, Li SQ, Fu SJ, Peng BG, Liang LJ (2014) Prognostic significance of glypican-3 in hepatocellular carcinoma: a meta-analysis. BMC Cancer 14:104

    Article  PubMed  PubMed Central  Google Scholar 

  9. Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, Filmus J (2003) Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 125(1):89–97

    Article  CAS  PubMed  Google Scholar 

  10. Shirakawa H, Kuronuma T, Nishimura Y, Hasebe T, Nakano M, Gotohda N, Takahashi S, Nakagohri T, Konishi M, Kobayashi N, Kinoshita T, Nakatsura T (2009) Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. Int J Oncol 34(3):649–656

    CAS  PubMed  Google Scholar 

  11. Llovet JM, Chen Y, Wurmbach E, Roayaie S, Fiel MI, Schwartz M, Thung SN, Khitrov G, Zhang W, Villanueva A, Battiston C, Mazzaferro V, Bruix J, Waxman S, Friedman SL (2006) A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 131(6):1758–1767

    Article  CAS  PubMed  Google Scholar 

  12. Wang XY, Degos F, Dubois S, Tessiore S, Allegretta M, Guttmann RD, Jothy S, Belghiti J, Bedossa P, Paradis V (2006) Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Hum Pathol 37(11):1435–1441

    Article  CAS  PubMed  Google Scholar 

  13. Zhang Q, Xiao Q, Lin Z, Ying X, Li Z, Lin JM (2010) Development of a competitive radioimmunoassay for glypican-3 and the clinical application in diagnosis of hepatocellular carcinoma. Clin Biochem 43(12):1003–1008

    Article  CAS  PubMed  Google Scholar 

  14. Yu JP, Xu XG, Ma RJ, Qin SN, Wang CR, Wang XB, Li M, Li MS, Ma Q, Xu WW (2015) Development of a clinical chemiluminescent immunoassay for serum GPC3 and simultaneous measurements alone with AFP and CK19 in diagnosis of hepatocellular carcinoma. J Clin Lab Anal 29(2):85–93

    Article  CAS  PubMed  Google Scholar 

  15. Lee HJ, Yeon JE, Suh SJ, Lee SJ, Yoon EL, Kang K, Yoo YJ, Kim JH, Seo YS, Yim HJ, Byun KS (2014) Clinical utility of plasma glypican-3 and osteopontin as biomarkers of hepatocellular carcinoma. Gut Liver 8(2):177–185

    Article  CAS  PubMed  Google Scholar 

  16. Badr EAE, Korah TE, Ghani AA, El-Sayed S, Badr S (2014) Role of serum glypican-3 in the diagnosis and differentiation of small hepatocellular carcinoma from hepatitis-C virus cirrhosis. Alexandria Journal of Medicine 50(3):221–226

    Article  Google Scholar 

  17. Ma RJ, Wang SH, Qin SN, Wang XB, Li GF, Li M, Xu WW (2012) Preparation and characterization of monoclonal antibody against glypican-3. Hybridoma (Larchmt) 31(6):455–461

    Article  CAS  Google Scholar 

  18. Fu SJ, Qi CY, Xiao WK, Li SQ, Peng BG, Liang LJ (2013) Glypican-3 is a potential prognostic biomarker for hepatocellular carcinoma after curative resection. Surgery 154(3):536–544

    Article  PubMed  Google Scholar 

  19. Ning S, Bin C, Na H, Peng S, Yi D, Xiang-hua Y, Fang-yin Z, Da-yong Z, Rong-cheng L (2012) Glypican-3, a novel prognostic marker of hepatocellular cancer, is related with postoperative metastasis and recurrence in hepatocellular cancer patients. Mol Biol Rep 39(1):351–357

    Article  CAS  PubMed  Google Scholar 

  20. Xu C, Yan Z, Zhou L, Wang Y (2013) A comparison of glypican-3 with alpha-fetoprotein as a serum marker for hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol 139(8):1417–1424

    Article  CAS  PubMed  Google Scholar 

  21. Qiao SS, Cui ZQ, Gong L, Han H, Chen PC, Guo LM, Yu X, Wei YH, Ha SA, Kim JW, Jin ZT, Li S, Peng JR, Leng XS (2011) Simultaneous measurements of serum AFP, GPC-3 and HCCR for diagnosing hepatocellular carcinoma. Hepato-Gastroenterology 58(110–111):1718–1724

    CAS  PubMed  Google Scholar 

  22. Abdelgawad IA, Mossallam GI, Radwan NH, Elzawahry HM, Elhifnawy NM (2013) Can Glypican3 be diagnostic for early hepatocellular carcinoma among Egyptian patients? Asian Pac J Cancer Prev 14(12):7345–7349

    Article  PubMed  Google Scholar 

  23. Yu J, Ma Q, Zhang B, Ma R, Xu X, Li M, Xu W, Li M (2013) Clinical application of specific antibody against glypican-3 for hepatocellular carcinoma diagnosis. Sci China Life Sci 56(3):234–239

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This study was funded by Industry-university-research Collaborative Innovation Major Projects of Guangzhou Science and Technology Planning Project, China (grant number. 201508020052).

Author information

Author notes

  1. Juan-Juan Chen and Chun-Mei Xie contributed equally to this work.

Authors and Affiliations

  1. State Key Laboratory of Organ Failure Research, Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, 510515, People’s Republic of China

    Juan-Juan Chen, Chun-Mei Xie, Ming Li & Wei-Wen Xu

  2. Department of Laboratory Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, People’s Republic of China

    Chun-Mei Xie & Cong-Rong Wang

  3. DaRui Biotechnology Co., Ltd, Guangzhou, 510655, People’s Republic of China

    Chun-Mei Xie, Yong Wan & Zhi-Ning Dong

Authors
  1. Juan-Juan Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chun-Mei Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cong-Rong Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yong Wan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zhi-Ning Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ming Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Wei-Wen Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Ming Li or Wei-Wen Xu.

Ethics declarations

Conflicts of Interest

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chen, JJ., Xie, CM., Wang, CR. et al. Development of a Time-Resolved Fluorescence Immunoassay for the Diagnosis of Hepatocellular Carcinoma Based on the Detection of Glypican-3. J Fluoresc 27, 1479–1485 (2017). https://doi.org/10.1007/s10895-017-2087-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10895-017-2087-1

Keywords

Search

Navigation